Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9

被引：33

作者：

Ashok, Bhaargavi ^{[1
]}

Peppas, Nicholas A. ^{[1
,2
,3
,4
,5
]}

Wechsler, Marissa E. ^{[6
]}

机构：

[1] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA

[2] Univ Texas Austin, Inst Biomat Drug Delivery & Regenerat Med, Austin, TX 78712 USA

[3] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA

[4] Univ Texas Austin, Coll Pharm, Div Mol Pharmaceut & Drug Delivery, Austin, TX 78712 USA

[5] Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, Austin, TX 78712 USA

[6] Univ Texas San Antonio, Dept Biomed Engn & Chem Engn, San Antonio, TX 78249 USA

来源：

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY | 2021年 / 65卷

基金：

美国国家卫生研究院;

关键词：

Hydrogels; Nanoparticles; CRISPR; Genome editing; IN-VIVO; TARGETED DELIVERY; MESSENGER-RNA; T-CELLS; GENE; CARRIERS; CANCER; VITRO; DNA; CRISPR-CAS9;

D O I：

10.1016/j.jddst.2021.102728

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The discovery of clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) genome editing systems and their applications in human health and medicine has heralded a new era of biotechnology. However, the delivery of CRISPR therapeutics is arguably the most difficult barrier to overcome for translation to in vivo clinical administration. Appropriate delivery methods are required to efficiently and selectively transport all gene editing components to specific target cells and tissues of interest, while minimizing off-target effects. To overcome this challenge, we discuss and critique nanoparticle delivery strategies, focusing on the use of lipid-based and polymeric-based matrices herein.

引用

页数：13

共 50 条

[31] Lipid- and Polymer-Based Nanostructures for Cancer Theranostics
Luk, Brian T.
Fang, Ronnie H.
Zhang, Liangfang
THERANOSTICS, 2012, 2 (12): : 1117 - 1126
[32] Development of a nanoparticle formulation for delivery of a CRISPR/Cas9 gene therapy for cystic fibrosis
Walker, A.
Guerrini, I.
Avgerinou, A.
Hart, S.
HUMAN GENE THERAPY, 2018, 29 (12) : A112 - A112
[33] CRISPR/Cas9
杨丽
中南医学科学杂志, 2016, 44 (05) : 585 - 585
[34] CRISPR/Cas9
Mizuno, Naoaki
Mizutani, Eiji
Sato, Hideyuki
Kasai, Mariko
Nakauchi, Hiromitsu
Yamaguchi, Tomoyuki
BIO-PROTOCOL, 2019, 9 (13):
[35] Editorial: Current approaches to CRISPR/Cas9 delivery
Uludag, Hasan
Aliabadi, Hamidreza Montazeri
Gasiunas, Giedrius
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10
[36] Recent Advances in CRISPR/Cas9 Delivery Strategies
Yip, Bon Ham
BIOMOLECULES, 2020, 10 (06)
[37] Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, Xiaojie
Wan, Tao
Xin, Huhu
Li, Da
Pan, Hongming
Wu, Jun
Ping, Yuan
JOURNAL OF GENE MEDICINE, 2019, 21 (07):
[38] Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing
Zhang, Zhen
Wan, Tao
Chen, Yuxuan
Chen, Yu
Sun, Hongwei
Cao, Tianqi
Zhou Songyang
Tang, Guping
Wu, Chuanbin
Ping, Yuan
Xu, Fu-Jian
Huang, Junjiu
MACROMOLECULAR RAPID COMMUNICATIONS, 2019, 40 (05)
[39] Nanoparticle delivery of CRISPR/Cas9 for treatment of cystic fibrosis by homology independent targeted integration
Walker, A.
Guerrini, I.
Woodall, M.
Hart, S.
HUMAN GENE THERAPY, 2019, 30 (11) : A188 - A188
[40] Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment
Lin, Meng
Wang, Xueyan
PHARMACEUTICS, 2024, 16 (01)

← 1 2 3 4 5 →